Ubiquitin-mediated signalling and Paget's disease of bone

BMC Biochemistry

Volumn 8, Issue SUPPL. 1, 2007, Pages

  Layfield, Robert ^a   Shaw, Barry ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P62; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; UBIQUITIN;

APOPTOSIS; BINDING AFFINITY; BONE MATRIX; CELL DIFFERENTIATION; GENE MUTATION; HYPERPHOSPHATEMIA; IN VITRO STUDY; MONOCYTE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOSARCOMA; PAGET BONE DISEASE; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; UBIQUITINATION; ANIMAL; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; OSTEITIS DEFORMANS; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 38449085976     PISSN: None     EISSN: 14712091     Source Type: Journal    
DOI: 10.1186/1471-2091-8-S1-S5     Document Type: Review

References (43)

1. Pathophysiology and treatment of Paget's disease of bone. JA Kanis, London: Martin Dunitz 1992
2. Incidence and natural history of Paget's disease of bone in England and Wales. TP van Staa P Selby HG Leufkens K Lyles JM Sprafka C Cooper, J Bone Miner Res 2002 17 465 471 10.1359/jbmr.2002.17.3.465 11878305
3. Osteogenic sarcoma of bones and soft tissues in older persons. A clinicopathologic analysis of 117 patients older than 60 years. AG Huvos, Cancer 1986 57 1442 1449 10.1002/1097-0142(19860401)57:7<1442::AID- CNCR2820570734>3.0.CO;2-3 2418941
4. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. GD Watts J Wymer MJ Kovach SG Mehta S Mumm D Darvish A Pestronk MP Whyte VE Kimonis, Nat Genet 2004 36 377 381 10.1038/ng1332 15034582
5. Genetics of Paget's disease of bone. A Daroszewska SH Ralston, Clin Sci (Lond) 2005 109 257 263 16104845
6. Detection of measles virus nucleocapsid transcripts in circulating blood cells from patients with Paget disease. SV Reddy FR Singer L Mallette GD Roodman, J Bone Miner Res 1996 11 1602 1607 8915767
7. Frequency and characteristics of familial aggregation of Paget's disease of bone. AA Morales-Piga JS Rey-Rey J Corres-Gonzalez JM Garcia-Sagredo G Lopez-Abente, J Bone Miner Res 1995 10 663 670 7610939
8. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. AE Hughes SH Ralston J Marken C Bell H MacPherson RG Wallace W Van Hul MP Whyte K Nakatsuka L Hovy DM Anderson, Nat Genet 2000 24 45 48 10.1038/71667 10615125
9. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. MP Whyte AE Hughes, J Bone Miner Res 2002 17 26 29 10.1359/jbmr.2002.17.1.26 11771666
10. Phenotypic characterisation of early onset Paget's disease of bone caused by a 27bp duplication in the TNFRSF11A gene. K Nakatsuka K Nishizawa SH Ralston, J Bone Miner Res 2003 18 1381 1385 10.1359/jbmr.2003.18.8.1381 12929927
11. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. H Hsu DL Lacey CR Dunstan I Solovyev A Colombero E Timms HL Tan G Elliott MJ Kelley I Sarosi, Proc Natl Acad Sci USA 1999 96 3540 3545 10097072 10.1073/pnas.96.7.3540
12. Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. BG Darnay J Ni PA Moore BB Aggarwal, J Biol Chem 1999 274 7724 7731 10.1074/jbc.274.12.7724 10075662
13. Osteoprotegerin deficiency and juvenile Paget's disease. MP Whyte SE Obrecht PM Finnegan JL Jones MN Podgornik WH McAlister S Mumm, N Engl J Med 2002 347 175 184 10.1056/NEJMoa013096 12124406
14. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. T Cundy M Hegde D Naot B Chong A King R Wallace J Mulley DR Love J Seidel M Fawkner, Hum Mol Genet 2002 11 2119 2127 10.1093/hmg/11.18.2119 12189164
15. Genetic regulation of osteoclast development and function. SL Teitelbaum FP Ross, Nat Rev Genet 2003 4 638 649 10.1038/nrg1122 12897775
16. SQSTM1 and Paget's disease of bone. R Layfield LJ Hocking, Calcif Tissue Int 2004 75 347 357 10.1007/s00223-004-0041-0 15365659
17. Polyubiquitin chains: polymeric protein signals. CM Pickart D Fushman, Curr Opin Chem Biol 2004 8 610 616 10.1016/j.cbpa.2004.09.009 15556404
18. Inclusion body myopathy associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. CC Weihl S Dalal A Pestronk PI Hanson, Hum Mol Genet 2006 15 189 199 10.1093/hmg/ddi426 16321991
19. VCP (p97) regulates NFkappaB signaling pathway, which is important for metastasis of osteosarcoma cell line. T Asai Y Tomita S Nakatsuka Y Hoshida A Myoui H Yoshikawa K Aozasa, Jpn J Cancer Res 2002 93 296 304 11927012
20. Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha. RM Dai E Chen DL Longo CM Gorbea CC Li, J Biol Chem 1998 273 3562 3573 10.1074/jbc.273.6.3562 9452483
21. The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. A Duran M Serrano M Leitges JM Flores S Picard JP Brown J Moscat MT Diaz-Meco, Dev Cell 2004 6 303 309 10.1016/S1534-5807(03)00403-9 14960283
22. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bone with a severe phenotype. SL Rea JP Walsh L Ward K Yip BK Ward GN Kent JH Steer J Xu T Ratajczak, J Bone Miner Res 2006 21 1136 1145 10.1359/jbmr.060405 16813535
23. Mutations in the RANK signal peptide alter the subcellular localisation of RANK and prevent ligand-dependent activation of NF kappa beta. JC Crockett A Duthie J Greenhorn DI Scott SH Ralston MH Helfrich MJ Rogers, J Bone Miner Res 2006 21 1154 [abstract]
24. p62, a phosphotyrosine-independent ligand of the SH2 domain of p56lck, belongs to a new class of ubiquitin-binding proteins. RK Vadlamudi I Joung JL Strominger J Shin, J Biol Chem 1996 271 20235 20237 10.1074/jbc.271.34.20235 8702753
25. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. N Laurin JP Brown J Morissette V Raymond, Am J Hum Genet 2002 70 1582 1588 11992264 10.1086/340731
26. Domain specific mutations in Sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. LJ Hocking GJA Lucas A Daroszewska J Mangion M Olavesen GC Nicholson L Ward ST Bennett W Wuyts W Van Hul SH Ralston, Hum Mol Genet 2002 11 2735 2739 10.1093/hmg/11.22.2735 12374763
27. Three novel mutations in SQSTM1 identified in familial Paget's disease of bone. TL Johnson-Pais JH Wisdom KS Weldon JD Cody MF Hansen FR Singer RJ Leach, J Bone Miner Res 2003 18 1748 1753 10.1359/jbmr.2003.18.10.1748 14584883
28. Two novel mutations at exon 8 of Sequestosome 1 gene (SQSTM1) in an Italian serie of patients affected by Paget's disease of bone (PDB). A Falchetti M Di Stefano F Marini F Del Monte C Mavilia D Strigoli ML De Feo G Isaia L Masi A Amedei, J Bone Miner Res 2004 19 1013 1017 10.1359/JBMR.040203 15125799
29. Familial Paget's disease in The Netherlands: occurrence, identification of new mutations in the sequestosome 1 gene, and their clinical associations. EW Eekhoff M Karperien D Houtsma AH Zwinderman C Dragoiescu AL Kneppers SE Papapoulos, Arthritis Rheum 2004 50 1650 1654 10.1002/art.20224 15146436
30. Novel UBA domain mutations of SQSTM1 in Paget's disease of bone: genotype phenotype correlation, functional analysis and structural consequences. LJ Hocking GJA Lucas A Daroszewska T Cundy GC Nicholson J Donath JP Walsh C Finlayson JR Cavey B Ciani, J Bone Miner Res 2004 19 1122 1127 10.1359/JBMR.0403015 15176995
31. Loss of ubiquitin-binding associated with Paget's disease of bone p62 (SQSTM1) mutations. JR Cavey SH Ralston LJ Hocking PW Sheppard B Ciani MS Searle R Layfield, J Bone Miner Res 2005 20 619 624 10.1359/JBMR.041205 15765181
32. Loss of ubiquitin binding is a unifying mechanism by which mutations of SQSTM1 cause Paget's disease of bone. JR Cavey SH Ralston PW Sheppard B Ciani TR Gallagher JE Long MS Searle R Layfield, Calcif Tissue Int 2006 78 271 B277 10.1007/s00223-005-1299-6 16691492
33. p62 mutations, ubiquitin recognition, and Paget's disease of bone. R Layfield JR Cavey D Najat J Long PW Sheppard SH Ralston MS Searle, Biochem Soc Trans 2006 34 735 737 10.1042/BST0340735 17052185
34. The p62 scaffold regulates nerve growth factor-induced NF-kappaB activation by influencing TRAF6 polyubiquitination. MW Wooten T Geetha ML Seibenhener JR Babu MT Diaz-Meco J Moscat, J Biol Chem 2005 280 35625 B35629 10.1074/jbc.C500237200 16079148
35. Recent advances in understanding the mechanism of action of bisphosphonates. FP Coxon K Thompson MJ Rogers, Curr Opin Pharmacol 2006 6 307 312 10.1016/j.coph.2006.03.005 16650801
36. The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma. LA Ehrlich GD Roodman, Immunol Rev 2005 208 252 266 10.1111/j.0105-2896.2005.00323.x 16313353
37. Mechanism of osteoclast mediated bone resorption- rationale for the design of new therapeutics. K Vaananen, Adv Drug Deliv Rev 2005 57 959 971 10.1016/j.addr.2004.12.018 15876398
38. OPG/membranous-RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. SK Tat M Padrines S Theoleyre S Couillaud-Battaglia D Heymann F Redini Y Fortun, Bone 2006 39 706 715 10.1016/j.bone.2006.03.016 16750945
39. Denosumab in postmenopausal women with low bone mineral density. MR McClung EM Lewiecki SB Cohen MA Bolognese GC Woodson AH Moffett M Peacock PD Miller SN Lederman CH Chesnut, N Engl J Med 2006 354 821 B831 10.1056/NEJMoa044459 16495394
40. Recombinant osteoprotegerin for juvenile Paget's disease. T Cundy J Davidson MD Rutland C Stewart AM DePaoli, N Engl J Med 2005 353 918 923 10.1056/NEJMoa050893 16135836
41. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. SQ Harper PD Staber X He SL Eliason IH Martins Q Mao L Yang RM Kotin HL Paulson BL Davidson, Proc Natl Acad Sci USA 2005 102 5820 5825 15811941 10.1073/pnas.0501507102
42. Lysine 63 polyubiquitination of the nerve growth factor receptor TrkA directs internalization and signaling. T Geetha J Jiang MW Wooten, Mol Cell 2005 20 301 312 10.1016/j.molcel.2005.09.014 16246731
43. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. E Jimi K Aoki H Saito F D'Acquisto MJ May I Nakamura T Sudo T Kojima F Okamoto H Fukushima, Nat Med 2004 10 617 624 10.1038/nm1054 15156202